Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eyedrops aim to soothe dry, irritated eyes

NCT ID NCT05586152

Symptom relief Sponsor: Invirsa, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental eyedrop called INV-102 in 84 adults with moderate dry eye disease. The study had two parts: first, checking safety at different doses, and second, seeing if the drops improve eye dryness symptoms after two weeks. Participants used the drops or a placebo (vehicle) twice daily. The goal is to find a new option for people whose dry eyes aren't helped by current treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
INV-102 ophthalmic solution (eyedrops)
What this could lead to
If successful, this could lead to a new eyedrop treatment that eases dryness and discomfort in people with moderate dry eye disease.
What could go wrong
This is an early first-in-human study with only 84 participants and short 2-week dosing. The treatment may not prove effective or safe in larger, longer trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

84 people

The number who actually took part.

Started

Aug 2022

Finished

May 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Healthy male or female subject ≥18 years of age * Presence of moderate DED in at least one eye Key Exclusion Criteria: * Presently using prescription eyedrops, except those used for DED, which must be discontinued 2 weeks prior * Use of OTC eyedrops except for lubricant eyedrops or artificial tears, within 1 week prior to initiation of study drug dosing * External eye disease except primary DED * Systemic disease associated with DED * History or evidence of ocular infection within the previous 30 days * History or evidence of ocular herpes simplex or ocular herpes zoster * Blepharitis or meibomian gland disease requiring the use of either topical or systemic antibiotics within 2 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye disease

Contacts and locations

Locations

  • iuvo BioScience

    Rush, New York, 14543, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.